Biotech and Pharmaceuticals Pharmaceuticals

  • swine_flu_needle_200.jpg

    Tackling the subject of improving health is complex and to know where we can have the most effect, sparks a lengthy and challenging debate. As the world continues to evolve, science will continue to offer exciting new discoveries. But it will also see the appearance of new diseases, the evolution of existing diseases and the re-emergence of old diseases to continually challenge the state of our health. However, for me, it is chronic disease that is the biggest healthcare challenge facing us, which has been largely unforeseen and is not being addressed adequately.

  • Mail-order drug pharmacy Medco Health Solutions will have a “monster” year, meaning a very lucrative one, in 2012, due to a number of blockbuster drugs going off-patent, David Snow, its CEO and chairman, told CNBC Monday.

  • brain_xrays_1_200.jpg

    A growing form of radiation therapy injures patients when its pinpoint beam is allowed to spread too far. The New York Times reports.

  • The "Mad Money" host explains why getting past this key level means stocks could go higher still.

  • Orexigen

    Investors sent shares of diet drug makers soaring Wednesday, one day after an FDA advisory panel recommended approval of Orexigen Therapeutic's weight loss drug Contrave.

  • Genzyme

    Despite the declaration that the “ingredients are there” for a deal between Genzyme Corp and Sanofi-Aventis but at a higher price, consensus among investors seem to be that Sanofi won’t be raising their bid of $69/share

  • Health care protestor.

    Congress will tweak but not repeal health care legislation, insurers won't take a bit hit from reform measures, sector consolidation will continue and China will drive growth for drug and device makers.

  • Genzyme

    Sanofi is focused on that tender, but only on whether to extend it. Here's why.

  • Techs or pharmeceuticals — which is the better buy for investors? Uri Landesman, president of Platinum Partners and Philip Tasho, CEO and CIO at Tamro Capital shared their insights.

  • Marijuana & Money: A CNBC Special Report

    Dixie Elixirs makes a line of pot-infused drinks and eats that it sells to medical centers in Colorado.

  • Stethescope and money

    Employers cannot balance their commitment to employee health benefits, double-digit healthcare inflation, shifting costs to employees, and responsibilities to shareholders. Something has to change.

  • republican_democrat_pin_200.jpg

    I’ve lived through many presidential and mid-term elections, and I don’t recall seeing this level of anguish, frustration, and outright anger from the American people. We’re in unchartered territory.

  • How can investors profit from health care? Uri Landesman, president of Platinum Partners and Doug Roberts, chief investment strategist at Channel Capital Research shared their favorite plays on the sector.

  • Six in 60

    Here's why you should keep a close eye on these six stocks.

  • company_solved_healthcare_150.jpg

    In writing, "Health care is mentioned every 20 seconds in one form of media or another. There’s little debate that something must to be done about the ever-rising health care costs; the point of contention is the what," one author offers his company's prescription.

  • Six in 60

    Here's why you should keep a close eye on these six stocks.

  • Nanny with Stroller

    Denture wearers will get a tax break on the cost of adhesives to keep their false teeth in place. But nursing mothers will not be allowed to use their tax-sheltered health care accounts to pay for breast pumps and other supplies, reports the New York Times.

  • bristol_myers_squibb.jpg

    Bristol-Myers Squibb posted a slight decline in third-quarter profit Tuesday as its restrained spending was offset by flat sales of its drugs, lower income from its partners and bigger discounts to government due to the health care overhaul.

  • Amgen

    The biotech firm reported earnings and revenue that beat expectations Monday, though it wasn't enough to lift the company's stock in late trading Monday.

  • cancer_treatment_200.jpg

    The insurers have begun tightening oversight of the care provided to patients with many different types of cancer, hoping to lower expenses by experimenting with new ways to pay specialists. The NYT reports.